April 2022

07 Apr New Results from the ILLUMINATE-A Study of OXLUMO® (lumasiran) Presented at NKF Spring Meetings

New findings from a 24-month analysis of the ongoing ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran) in patients with primary hyperoxaluria type 1 (PH1) were presented during the National Kidney Foundation (NKF) Spring Clinical Meetings (April 6-10, 2022). Lieske, et al. “Efficacy and Safety of Lumasiran...

04 Apr New Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at ACC

New results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic, in hereditary transthyretin-mediated (hATTR) amyloidosis patients with polyneuropathy, were presented during a poster presentation at the 71st Annual Meeting of the American College of Cardiology (ACC) held April 2–4, 2022. The...

21 Jan 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at SFNP

Positive 18-month results from the HELIOS-A Phase 3 study evaluating vutrisiran, an investigational RNAi therapeutic, in hereditary transthyretin-mediated (hATTR) amyloidosis patients with polyneuropathy, were presented in an oral session at the Société Francophone du Nerf Périphérique (SFNP) Annual Meeting, held January 21-22, 2022. Read the press release Adams et al. – “HELIOS-A: Study of Vutrisiran in Patients with hATTR Amyloidosis”